Autologous transplant in multiple myeloma with an augmented conditioning protocol

Badran Abu Zaid, Ali Abdul-Hai, Itamar Grotto, Lillian Dray, Igor B. Resnick, Panagiotis D. Tsirigotis, Simcha Samuel, Reuven Or, Michael Y. Shapira

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


We compared the tolerability and anti-myeloma effect of two conditioning regimens for autologous stem cell transplant (auto-SCT) in consecutive groups of patients. Protocol 1 was the earlier, and consisted of the combination of three agents in a sequential manner, including etoposide, thiotepa and melphalan (n = 29), while protocol 2 employed melphalan alone (n = 34). The two groups were comparable (other than younger age in protocol 1). Conditioning with protocol 1 seemed more toxic, as expressed by the higher number of febrile days and higher demand for parenteral nutrition. This was not expressed with longer admission time. With 108 and 60 months' median follow-up, respectively, the median survival in patients treated by protocol 2 (melphalan 200 mg/m2) was reached at 59 months, while the median survival was not yet reached in patients treated with protocol 1 (p = 0.039). The time to progression was significantly longer with protocol 1 (median 44 months vs. 17 months with protocol 2, p = 0.033). Confounded by the small number of patients, conditioning with melphalan augmented by etoposide and thiotepa in a sequential manner is slightly more toxic than melphalan alone and may benefit patients with myeloma undergoing auto-SCT.

Original languageEnglish
Pages (from-to)2480-2484
Number of pages5
JournalLeukemia and Lymphoma
Issue number11
StatePublished - 21 Oct 2013


  • Autologous bone marrow transplant
  • Conditioning regimen
  • Multiple myeloma
  • Toxicity


Dive into the research topics of 'Autologous transplant in multiple myeloma with an augmented conditioning protocol'. Together they form a unique fingerprint.

Cite this